Syndax Pharmaceuticals Reports Third Quarter 2026 Financial Results

Syndax Pharmaceuticals reported third-quarter 2026 revenue of $83.3 million, including $60.7 million from Revuforj and $22.6 million in Niktimvo collaboration revenue. Its net loss attributable to common stockholders narrowed to $49.4 million, or $0.55 per share, from $60.7 million a year earlier. Revuforj growth was supported by a 20% increase in new patients. Syndax reaffirmed its 2026 outlook for approximately $400 million in combined R&D and SG&A expenses, excluding non-cash stock compensation.